LAUSR

e20040Background: Longitudinal tumor burden has long been used for the clinical diagnosis, staging, prognosis and treatment of non-small cell lung cancer (NSCLC). Tumor burden and growth rate correlate directly with survival and RECIST (measurement of tumor) is widely used as a surrogate endpoint. RECIST doesn’t take into account the impact of the therapy on the speed of growth over time, and poorly correlates with survival, especially in IO therapies. Surrogate endpoints such as progression-free survival (PFS) or dichotomous RECIST-based overall response rate (ORR) allow early assessment of efficacy based on reduced study population size. Unfortunately, ORR and PFS are poorly predictive of OS in NSCLC. This well-known loss of information during categorization emphasizes the potential benefits of continuous tumor load modeling. Methods: This research provides a statistically valid basis for modeling and interpretation of longitudinal response dynamics, in the context of time-to-event (survival) censoring,...